When is Rebus Holdings’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Rebus Holdings’s earnings last quarter?
Rebus Holdings released its earnings results on Apr 01, 2021. The company reported -$3.642 earnings per share for the quarter.
Is Rebus Holdings overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Rebus Holdings pay dividends?
Rebus Holdings does not currently pay dividends.
What is Rebus Holdings’s EPS estimate?
Rebus Holdings’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Rebus Holdings have?
Rebus Holdings has 32,132,908 shares outstanding.
What happened to Rebus Holdings’s price movement after its last earnings report?
Rebus Holdings reported an EPS of -$3.642 in its last earnings report. Following the earnings report the stock price went same ―.
Which hedge fund is a major shareholder of Rebus Holdings?
Currently, no hedge funds are holding shares in RBSH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Rebus Holdings
Rebus Holdings, Inc. is dedicated to pioneering highly targeted therapies for oncology. Its flagship investigational product, RT-AR001, operates as an adenosine receptor antagonist. This compound, when administered directly into cancerous growths, is engineered to diminish tumor invasion and improve therapeutic efficacy. The corporation was established in 2003 and maintains its headquarters in Westlake Village, California.
Sector
Healthcare
Industry
Biotechnology
CEO
Raul Silvestre
Employees
1
Website
www.rebus-corp.com
Address
2629 Townsgate Road, Westlake Village, CA, 91361, US